Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
tyrosine kinase inhibitors
Biotech
BridgeBio preps approval push for dwarfism drug after ph. 3 win
BridgeBio is hoping infigratinib will get another shot at approval after the medicine hit the key goals of a phase 3 study in a form of dwarfism in children.
James Waldron
Feb 12, 2026 7:30am
Fierce Pharma
Exelixis aims to be a top 5 solid tumor drugmaker in the US: CEO
Jan 16, 2026 1:00pm
Galapagos' last immunology asset posts mixed results
Dec 19, 2025 6:05am
Takeda looks to 2026 FDA filing for Sotyktu rival zasocitinib
Dec 18, 2025 7:55am
ESMO: Exelixis' TKI reduces risk of death by 20%
Oct 20, 2025 2:30am
Nuvalent trots out strong pivotal data in FDA lung cancer push
Jun 24, 2025 6:30am
